FL-ETT
ETT | iByond™, together with WorldVuer established WorldVuer iByond’s joint venture to develop the world’s first artificial intelligence operating system, WiOS (WorldVuer iByond Operating System). This collaboration is poised to modernize the technology estates of global enterprises, multinationals, sovereigns, and governments, leveraging intelligent interoperability, speed of innovation, AI, and an airtight security platform. “WiOS is poised to be one of the next big players to dominate the world stage alongside Android and iOS,” concluded Mr. Michael Sutton, Chief Media Officer of WorldVuer Inc.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240709427149/en/
Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc. & Christopher Condon, Chairman & CEO of ETT | iByond™ (Photo: Business Wire)
ETT | iByond™, renowned for its cutting-edge Intelligent Interoperability AI platform, offers seamless integration and intelligent solutions tailored to enhance business operations across various industries. With a commitment to driving technological advancement, iByond's platform empowers organizations to harness the power of AI, enabling smarter decision-making, improved efficiency, and significant cost savings for enterprises. The iByond platform will serve individual consumers with WorldVuers’ technology products. WorldVuer brings to this venture their existing ecosystem of customers, consisting of 25 countries and 98 Million households, estimated to bring this partnership USD $6 Billion+ in annual software subscription revenues. Additionally, WorldVuer has a diverse portfolio of seven pioneering technologies, each designed to push the boundaries of innovation. WorldVuer’s products are built with an emphasis on security, incorporating airtight cybersecurity measures to ensure the utmost protection for users.
“We are excited to partner with WorldVuer, a company that shares our vision of innovation and excellence,” said Christopher Condon, Chairman and CEO of ETT | iByond™. “This partnership will enable us to deliver an unparalleled AI operating system with the highest level of speed, security, and data connection helping governments and enterprises worldwide to thrive in an increasingly digital world.”
“Innovating an AI Operating System that is built to transition the current global interconnected cloud devices within our communities and countries into an efficient, corroborative, and dynamic Interoperable platform to power current and futuristic devices makes this initiative an exciting opportunity for both WorldVuer and ETT | iByond™,” commented by Dr. Kenneth Ekow Andam, CEO of WorldVuer Inc.
“As we continue to witness extensive adoption and investment in AI across the enterprise and consumer markets globally, the WorldVuer iByond operating system provides breakthrough innovation and value by integrating hardware, software, and platform technologies and services. speed, security, and scale are now in reach at a level far beyond the data management and AI solutions currently available.” Lanny Cohen, Vice-Chairman & CPO, ETT | iByond™
About WorldVuer iByond
At WorldVuer | iByond, a joint venture that provides cutting-edge intelligent technologies powered by the iByond | WiOS system, focused on Enhanced Security, Seamless Data Integration, Improved Data Governance, and Enhanced Collaboration. WorldVuer iByond provides top-tier data protection, smooth data flow, regulatory compliance, and efficient communication, empowering organizations to boost productivity, creativity, and competitiveness. For more information, visit www.worldvueribyond.com
About ETT | iByond™
ETT | iByond™ is a leading provider of transformative solutions for enterprises, specializing in software, infrastructure, and innovations. iByond empowers businesses to embrace digital transformation and unlock new avenues for growth and success in today’s rapidly evolving business environment connecting humanity through intelligent data. For more information, visit www.ettworld.com
About WorldVuer
Leaders in interactive content development. We build products to bring a lifestyle narrative and communications capabilities into your home and office. Buy WorldVuer products and join our new emerging media empowering solutions that help you build success for you and your family. For more information, visit www.wvistore.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240709427149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 12:30:00 CET | Press release
FDA Accepts Investigational New Drug (IND) Application for COMP360 for the treatment of post-traumatic stress disorder (PTSD), enabling initiation of late-stage trialCompass continues to advance commercial preparations to be launch-ready by the end of the year for COMP360 for treatment-resistant depression (TRD)Management will host webinar with KOL and industry leaders to discuss PTSD clinical trial and commercial preparations for TRD from 10:00-11:30 am ET on January 7th Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations f
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 11:07:00 CET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 10:00:00 CET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 09:00:00 CET | Press release
Acquisition will accelerate Ramudden’s ambitious growth plan across North America and Europe supported by strong infrastructure spending tailwinds I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that unde
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 09:00:00 CET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom